精神在线>NaSSA合理应用文献研究平台_您现在的位置:  >> 文摘精选 >> 米氮平最新临床研究目录 >> 文献正文
米氮平在改善癌症患者睡眠及控制焦虑和抑郁方面优于丙咪嗪
题目TitleMirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine

著者Authors】 Cankurtaran ES, Ozalp E, Soygur H, Akbiyik DI, Turhan L, Alkis N
来源Source】 Support Care Cancer. 2008 Feb 26
关键词Keywords】 Mirtazapine,cancer patients

摘要Abstract

癌症病人除本身疾病带来的症状外,还存在呕吐 、疼痛、 睡眠障碍,食欲不佳等症状,并且大多数患者有焦虑抑郁症状,本研究关注米氮平与丙咪嗪改善这些症状的疗效比较……

GOALS OF THE WORK: This study aimed to compare the effectiveness of mirtazapine and imipramine on not only the distressing symptoms of cancer patients such as pain, nausea, vomiting, appetite loss, and sleep disturbances but also depressive and anxiety symptoms.

MATERIALS AND METHODS: Fifty-three patients with cancer who were diagnosed with major depressive disorder, anxiety disorder, or adjustment disorder were included. Twenty patients on mirtazapine, 13 patients on imipramine, and 20 patients in the control group without medication were interviewed during three visits (baseline, third week, and sixth week). Pain, nausea, vomiting, appetite loss, and sleep disturbances were evaluated with self-assessment single-symptom scales during each visit. The patients were also asked to complete the Hospital Anxiety Depression Scale (HADS) during each visit.

MAIN RESULTS: There were no significant differences among the three visits in the mirtazapine, imipramine, or control groups in terms of pain, nausea, vomiting, or appetite loss. For the initial, middle, and late insomnia, only the mirtazapine group showed improvements (p = 0.001, p = 0.001, p = 0.003). There were also significant differences in the mean total (p = 0.03), anxiety (p = 0.003), and depression (p = 0.025) scores of HADS among the three visits for patients taking mirtazapine. There were no significant differences for HADS scores from the baseline to the end point for patients taking imipramine or control group patients.

CONCLUSION: Our findings suggest that mirtazapine is effective for resolving insomnia as well as anxiety and depressive symptoms in cancer patients. However, more systematic research, such as placebo-controlled studies, is needed.


  • 上一篇文献:
  • 下一篇文献:

  • 相关文献
    米氮平在青少年神经性厌食症治疗中的应用:病例对照研究
    一项随机双盲研究:米氮平和阿米替林在共病抑郁障碍的酗酒患者中的疗效与耐受性
    一个开放的、长期的、自然的研究米氮平治疗伴随抑郁症的癌症患者
    术前应用米氮平能降低术前焦虑和术后恶心、呕吐
    米氮平治疗慢性紧张型头痛的效果:文献回顾
    米氮平对与SSRI的应用有关的抑郁患者性功能障碍的作用
    米氮平提高健康人对疼痛的耐受性,有助于神经性疼痛患者的治疗
    米氮平和情绪稳定剂联合治疗对抑郁患者血药浓度的影响
    米氮平过量无显著毒性:一个5年回顾性病例分析
    米氮平不影响抑郁患者tetrahydrodeoxycorticosterone水平
    单独使用米氮平治疗的毒性研究结果探讨



    精神在线网 复旦大学医学院精神卫生学系 合办
    本站专业医学信息和服务仅供中国医疗专业人士参考

    © 精神在线网 PsyCard.Com
    精神/心理医学专业信息网络平台、博客、论坛
    全站文章索引-SiteMap